OGI Bio is pleased to announce the appointment of Andrew Murphy as Chair of the Board of Directors. Andrew succeeds Stephen Roe who is stepping down as a Director following 3 years with OGI Bio. With his extensive experience in scaling high-growth businesses and providing strategic leadership, Andrew will play a crucial role in guiding OGI Bio through its next phase of expansion and innovation.
Andrew brings a wealth of expertise in the technology and life sciences sectors, having successfully led numerous companies through key growth stages. His appointment reflects OGI Bio’s commitment to building a strong and experienced leadership team as the company continues to transform the field of microbial culturing automation.
“We are delighted to welcome Andrew as Chair of the Board,” said Dr. Alex McVey, CEO of OGI Bio. “His insights, strategic vision, and track record of success have proved critical since he joined our team in 2022, and we’re thrilled he has renewed his commitment to the company by assuming the role of Chair. His expertise will be invaluable as we continue to scale our operations and drive innovation in the biotech sector.”
With Andrew’s leadership, OGI Bio is well-positioned to accelerate its growth and continue delivering groundbreaking solutions to researchers worldwide.